子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 141 | Markers of the male urogenital tract | US15360240 | 2016-11-23 | US10006921B2 | 2018-06-26 | Keith Jarvi; Eleftherios P. Diamandis; Andrei Drabovich |
| Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides, encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers. | ||||||
| 142 | Method for detection of, or the risk of, bladder cancer | US13386228 | 2010-07-29 | US09562905B2 | 2017-02-07 | Mark W. Ruddock; Cherith N. Reid; Kathleen Williamson; John V. Lamont; Stephen P. Fitzgerald |
| Methods for the detection of, or the risk of, bladder cancer in a patient, comprising assaying for the presence of a combination of at least two biomarkers selected from CEA, VEGF, IL-8, NGAL, NSE, IL-2, EGF, TM, d-Dimer, MMP-9, IL-6, IL-4, MMP-9/NGAL, FAS, CRP, TUP and NMP22 in one or more samples isolated from a patient wherein detecting the presence of a combination of at least two biomarkers in the one or more samples indicates the presence or risk of bladder cancer. | ||||||
| 143 | Methods and Devices for Detecting Kidney Damage | US15014993 | 2016-02-03 | US20160231332A1 | 2016-08-11 | Samuel T. LaBrie; James P. Mapes; Michael D. Spain; Ralph L. McDade; Dominic P. Eisinger; Karri L. Ballard |
| Methods and devices for diagnosing, monitoring, or determining kidney damage in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney damage using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | ||||||
| 144 | Cell-based detection of APF through its interaction with CKAP4 for diagnosis of interstitial cystitis | US13133244 | 2009-12-10 | US08962341B2 | 2015-02-24 | David Alan Zacharias; Sonia Lobo Planey |
| An assay system designed to detect a protein biomarker in urine that is diagnostic for interstitial cystitis (IC). The presence of a 9 amino acid glycopeptide, antiproliferative factor (APF), in urine is unique to patients with IC. Urine samples from patients who exhibit symptoms consistent with IC are added to the assay system. Binding of APF to the cytoskeletal associated protein 4 (CKAP4) is positive for the presence of APF in urine and diagnostic for IC. The diagnostic system is a significant and surprising advance in diagnosis of IC and has commercial applications relevant to women and men who suffer from symptoms consistent with IC. | ||||||
| 145 | Methods and devices for detecting obstructive uropathy and associated disorders | US12852236 | 2010-08-06 | US08735080B2 | 2014-05-27 | Samuel T. Labrie; James P. Mapes; Ralph L. McDade; Dominic Eisinger; Karri L. Ballard; Michael D. Spain |
| Methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | ||||||
| 146 | USE OF PERIOSTIN AS A NOVEL BIOMARKER | US14058099 | 2013-10-18 | US20140135227A1 | 2014-05-15 | Sharon Adler; Bancha Satirapoj; Ying Wang; Janine LaPage; Cynthia C. Nast |
| The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | ||||||
| 147 | Markers of the Male Urogenital Tract | US13814959 | 2011-08-16 | US20130210666A1 | 2013-08-15 | Keith Jarvi; Eleftherios P. Diamandis; Andrei Drabovich |
| Methods for detecting urogenital conditions or urogenital status in a subject are described comprising measuring urogenital markers or polynucleotides encoding the markers in a sample from the subject. The invention also provides localization or imaging methods for urogenital conditions, and kits for carrying out the methods of the invention. The invention also contemplates therapeutic applications for urogenital conditions employing urogenital markers, polynucleotides encoding the markers, and/or binding agents for the markers. | ||||||
| 148 | Methods for diagnosing interstitial cystitis via nuclear localization of beta-catenin | US12741265 | 2008-11-05 | US08415108B2 | 2013-04-09 | Jay E. Reeder; Robert D. Mayer; Mary O'Connell |
| Methods for diagnosing a pelvic pain disorder that include analyzing samples for increased levels and/or nuclear accumulation of beta-catenin, which indicates presence of the pelvic pain disorder, particularly interstitial cystitis. Therapeutic treatment of a pelvic pain disorder, particularly interstitial cystitis, includes the administration to a patient of an effective amount of an inhibitor of beta-catenin activity. This can be carried out by direct administration of the therapeutic agent or via gene therapy. | ||||||
| 149 | PODOCYTE PH MODULATION AND USES THEREOF | US13497451 | 2010-09-22 | US20120219542A1 | 2012-08-30 | Jochen Reiser |
| Compositions are directed to the treatment of kidney diseases in a cell-specific manner. Methods of treating kidney diseases comprise the use of the compositions. Assays for identification of further compounds are provided. Biomarkers for predisposition to kidney diseases and diagnosis are identified. | ||||||
| 150 | DIAGNOSING AND MONITORING RESPONSE TO TREATMENT OF SOLID ORGAN TISSUE DISEASE | US13130351 | 2009-11-20 | US20110229882A1 | 2011-09-22 | Martin Heath Bluth; Wellman Cheung |
| Techniques for diagnosing and monitoring response to treatment of a solid organ tissue disease in a patient are provided. For example, a technique for diagnosing a solid organ tissue disease in a patient includes obtaining at least one of one or more blood-derived nucleated acellular components and one or more nucleated cellular components from the patient to provide a reporter function in the patient. Also, a technique for monitoring response to treatment of a solid organ tissue disease in a patient includes obtaining at least one of one or more blood-derived nucleated acellular components and one or more nucleated cellular components from the patient to provide a reporter function in the patient. | ||||||
| 151 | DIAGNOSING AND MONITORING RESPONSE TO TREATMENT OF NON-INCONTINENT UROLOGICAL AND RELATED DISEASES | US13130362 | 2009-11-20 | US20110223603A1 | 2011-09-15 | Martin Heath Bluth; Wellman Cheung |
| Techniques for diagnosing and monitoring response to treatment of non-incontinent urological disorders (NIUD) in a patient are provided. For example, a technique for diagnosing NIUD in a patient includes obtaining peripheral blood-derived nucleic acid containing nucleated acellular components such as serum and/or plasma and/or nucleated cellular components from the patient to provide a reporter function in the patient. Also, a technique for monitoring response to treatment of NIUD in a patient includes obtaining peripheral blood-derived nucleic acid containing nucleated acellular components such as serum and/or plasma and/or nucleated cellular components from the patient to provide a reporter function in the patient. | ||||||
| 152 | Methods and Devices for Detecting Kidney Transplant Rejection | US12852322 | 2010-08-06 | US20110177959A1 | 2011-07-21 | Michael D. Spain; James P. Mapes; Samuel T. Labrie; Ralph L. McDade; Dominic P. Eisinger; Karri L. Ballard; Daniel R. Salomon; Michael Abecassis |
| Methods and devices for diagnosing, monitoring, or determining kidney transplant rejection or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney transplant rejection or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | ||||||
| 153 | Use of periostin as a novel biomarker | US12924608 | 2010-09-29 | US20110177613A1 | 2011-07-21 | Sharon Adler; Bancha Satirapoj; Ying Wang; Janine LaPage; Cynthia C. Nast |
| The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | ||||||
| 154 | TETRAHYDRO-ISOALPHA ACID COMPOSITIONS AND METHODS FOR WEIGHT MANAGEMENT | US12856089 | 2010-08-13 | US20110136917A1 | 2011-06-09 | Matthew L. Tripp; Gary Darland; Veera Konda |
| Compositions and methods to promote or maintain weight loss utilizing tetrahydro-isoalpha acid compounds are disclosed. Methods to increase synthesis of GLP-1 are disclosed. | ||||||
| 155 | CTGF AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET | US12445737 | 2007-10-04 | US20110111394A1 | 2011-05-12 | Stefan Golz; Holger Summer; Andreas Geerts; Ulf Brüggemeier; Barbara Albrecht-Küpper; Martina Klein; Sonja Steppan; Peter Ellinghaus; Donatella D'Urso; Michael Seewald; Hendrik Milting |
| The invention provides CTGF which is associated with the cardiovascular diseases and hematological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases and hematological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CTGF as well as pharmaceutical compositions comprising such compounds. The invention also provides CTGF as a biomarker for diseases as cardiovascular diseases and hematological diseases | ||||||
| 156 | Methods and Devices for Detecting Obstructive Uropathy and Associated Disorders | US12852236 | 2010-08-06 | US20110065137A1 | 2011-03-17 | Samuel T. LaBrie; James P. Mapes; Ralph L. McDade; Dominic Eisinger; Karri L. Ballard; Michael D. Spain |
| Methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | ||||||
| 157 | Monoclonal antibodies against osteopontin | US11978796 | 2007-10-30 | US07867725B2 | 2011-01-11 | Lucy Liaw; Ah-Kau Ng |
| The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis. | ||||||
| 158 | METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN | US12741265 | 2008-11-05 | US20100292170A1 | 2010-11-18 | Jay E. Reeder; Robert D. Mayer; Mary O'Connell |
| Methods for diagnosing a pelvic pain disorder that include analyzing samples for increased levels and/or nuclear accumulation of beta-catenin, which indicates presence of the pelvic pain disorder, particularly interstitial cystitis. Therapeutic treatment of a pelvic pain disorder, particularly interstitial cystitis, includes the administration to a patient of an effective amount of an inhibitor of beta-catenin activity. This can be carried out by direct administration of the therapeutic agent or via gene therapy. | ||||||
| 159 | Method of treating bladder and lower urinary tract syndromes | US10268969 | 2002-10-11 | US07829545B2 | 2010-11-09 | Debra A. Schwinn |
| The present invention relates to bladder and lower urinary tract syndromes, particularly, irrative symptoms, and to a method of treating same using α1d-adrenergic receptor (α1dAR) antagonists. The invention further relates to a method of screening compounds for their ability to serve as α1dAR selective antagonists. | ||||||
| 160 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | US12742781 | 2008-11-14 | US20100266504A1 | 2010-10-21 | Takahiro Matsumoto; Hiroyuki Nagamiya; Hironobu Maezaki; Tomokazu Kusumoto; Kyoko Yoshikawa; Hideki Furukawa; Izumi Kamo |
| Provided are a condensed pyridine derivative having a serotonin 5-HT2C receptor activation action, a prophylactic or therapeutic agent for a lower urinary tract symptom, obesity and/or organ prolapse and the like containing the condensed pyridine derivative, a screening method for a substance that increases leak point pressure upon a rise in the intravesical pressure or a prophylactic or therapeutic drug for stress urinary incontinence, a prophylactic or therapeutic drug for cystoceles or enteroceles, containing a substance that activates serotonin 5-HT2C receptor, and a method of screening for a therapeutic drug for cystoceles or enteroceles, including increasing an intravesical pressure after bilateral transection of the hypogastric nerve and pudendal nerve of an animal, and measuring a closure response in the urethra, the rectum or the vagina observed at that time. A serotonin 5-HT2c receptor activator containing a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof. | ||||||
QQ群二维码
意见反馈
意见反馈